Ocugen Shares Extend Losses to Fifth Consecutive Session

Ocugen's stock continues its downward trajectory, marking a fifth straight day of losses. The biotech firm's shares have now closed lower in nine of the past ten trading sessions, reflecting growing investor pessimism. Despite the company's promising gene therapy pipeline, market participants appear unconvinced about its near-term prospects.

The company's latest quarterly report reveals a rapidly expanding financial deficit. For the third quarter of 2025, Ocugen reported a net loss exceeding $20 million, representing a substantial increase from the approximately $13 million loss recorded during the same period last year. On a per-share basis, the loss widened from $0.05 to $0.07, indicating a deteriorating financial foundation.

Mounting research and development expenditures are placing significant pressure on the company's resources. As Ocugen advances its gene therapy portfolio, including the OCU410 program targeting geographic atrophy, these ambitious initiatives are consuming substantial capital. Rather than rewarding these long-term investments, the market is currently focusing intently on the challenging present financial metrics.

Should investors sell immediately? Or is it worth buying Ocugen?

Technical Indicators Flash Warning Signs

From a technical analysis perspective, the outlook appears equally concerning. Both short-term and long-term moving averages are generating sell signals, with the long-term average positioned above the short-term average – a classic configuration indicating sustained downward momentum. During Wednesday's session, the stock declined another 0.87 percent while experiencing an intraday trading range of 8.11 percent between its high and low points, highlighting significant volatility and investor anxiety.

The fundamental challenge facing Ocugen remains clear: management must persuade investors that its gene therapy pipeline's long-term potential justifies the mounting short-term losses. However, as financial losses continue to accelerate, selling pressure on the stock appears likely to persist.